Author:
Kovaleva O. V.,Podlesnaya P. A.,Mochalnikova V. V.,Kushlinskii N. E.,Gratchev A. N.
Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. Esteller M. Non-coding RNAs in human disease. Nat. Rev. Genet. 2011;12(12):861-874. https://doi.org/10.1038/nrg3074
2. Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36(41):5661-5667. https://doi.org/10.1038/onc.2017.184
3. Xiao L, Shi XY, Li ZL, Li M, Zhang MM, Yan SJ, Wei ZL. Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway. J. Gynecol. Oncol. 2021;32(5):e77. https://doi.org/10.3802/jgo.2021.32.e77
4. Wu Z, Ouyang C, Peng L. Risk assessment model and nomogram established by differentially expressed lncRNAs for early-stage lung squamous cell carcinoma. Transl. Cancer Res. 2020;9(9):5304-5314. https://doi.org/10.21037/tcr-20-999
5. Ouyang D, Su J, Huang P, Li M, Li Q, Zhao P, Chen Q, Zou Q, Feng X, Qian K, Li L, Yi W. Identification of lncRNAs via microarray analysis for predicting HER2-negative breast cancer response to neoadjuvant chemotherapy. Int. J. Clin. Exp. Pathol. 2018;11(5):2621-2628.